Trials / Withdrawn
WithdrawnNCT00242359
A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bernstein Clinical Research Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Management of animal induced occupational asthma is mainly avoidance, but this is not feasible for many occupations. Treatment with avoidance and conventional treatment is also not always successful. Omalizumab is FDA approved for the treatment of allergic asthma and may be effective at reducing symptoms and disease progression in the animal handlers population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | omalizumab |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2005-10-20
- Last updated
- 2019-07-10
Source: ClinicalTrials.gov record NCT00242359. Inclusion in this directory is not an endorsement.